OSU6162 in Bipolar Depression (OBID)

Summary

An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.

Timeline

Start

2021-10-25

Primary completion

2026-05-31

Completion

2027-05-31

Drugs

Indications